2024
Validation of Recent Response Criteria (ELN-22, IWG-23 and PB-CR) in 1634 MDS/CMML/AML Patients Treated with HMA or HMA-Ven Using CPH Models and a CPH Deep Neural Network - Can or Should Response Criteria be Harmonized for Similarly Treated Patients?
Pleyer L, Vaisband M, Klammer P, Drost M, Angermann H, Keil F, Petzer V, Heibl S, Moritz J, Girschikofsky M, Stampfl-Mattersberger M, Pichler A, Hartmann B, Aschauer G, Schmitt C, Vallet S, Boros S, Pichler P, Hammerl-Steiner A, Renneberg F, Majjiga D, Russ G, Egle A, Leisch M, Melchardt T, Zaborsky N, Faber V, Bewersdorf J, Zeidan A, Hasenauer J, Greil R. Validation of Recent Response Criteria (ELN-22, IWG-23 and PB-CR) in 1634 MDS/CMML/AML Patients Treated with HMA or HMA-Ven Using CPH Models and a CPH Deep Neural Network - Can or Should Response Criteria be Harmonized for Similarly Treated Patients? Blood 2024, 144: 7511-7511. DOI: 10.1182/blood-2024-208073.Peer-Reviewed Original ResearchComposite complete remissionTime to next treatmentCox proportional hazardsHypomethylating agentsOverall survivalCox proportional hazards modelsMedian OSResponse criteriaTreated ptsCycles of HMAHigher-risk MDSKaplan-Meier methodBone marrow evaluationProspective cohort studyStandard of careComplete remissionMarrow evaluationTreated patientsMultivariable adjustmentNext treatmentCohort studyClinical trialsClinical overlapHazard ratioDisease entity
2023
Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Winer E, Garcia J, Stone R, Wadleigh M, Luskin M, Stahl M, Chen E, Leonard R, Noyes A, Galinsky I, Deshpande R, Borderies P, O'Neill V, DeAngelo D. Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood 2023, 142: 1549. DOI: 10.1182/blood-2023-186598.Peer-Reviewed Original ResearchRelapsed/refractory AMLHypomethylating agentsMetastatic castration-resistant prostate cancerCycles of HMARecommended phase 2 doseRelapsed/Refractory Acute Myeloid LeukemiaAllogeneic bone marrow transplantationCastration-resistant prostate cancerHigh-risk myelodysplastic syndromeNon-small cell lung cancerOral small-molecule inhibitorPhase 2 doseNon-Hodgkin's lymphomaDuration of responseMaximum tolerated doseECOG performance statusT cell responsesAdequate renal functionBone marrow transplantationAdequate liver functionPhase 1 studyCell lung cancerInduction of IL-18Acute myeloid leukemiaActivation of inflammatory cytokines
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply